Skip to main content


Fig. 1 | Stem Cell Research & Therapy

Fig. 1

From: Priming with Toll-like receptor 3 agonist or interferon-gamma enhances the therapeutic effects of human mesenchymal stem cells in a murine model of atopic dermatitis

Fig. 1

Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) improve Aspergillus fumigatus (Af)-induced atopic dermatitis (AD) in a murine model. a Study design. A murine model of AD was developed by applying Af extract to the dorsal skin of BALB/c mice for five consecutive days and then repeating this application after 2 weeks. WJ-MSCs were subcutaneously injected on day 24 and the effects were examined on day 29. b Clinical symptom scores (left) and transepidermal water loss (TEWL, right) were determined after injection of high and low doses of WJ-MSCs. c Histopathologic features of skin lesions. (Top) Skin lesions were stained with haematoxylin-eosin to identify eosinophils, neutrophils and lymphocytes. (Bottom) Skin lesions were stained with toluidine blue to identify mast cells. Scale bar = 100 μm. d Numbers of eosinophils, neutrophils, mast cells and lymphocytes were counted under a microscope at × 200 magnification. Data are presented as the mean ± SEM (N = 6 per group). **, p < 0.005; ***, p < 0.0005 compared with the control group; #, p < 0.05; ##, p < 0.005 compared with the AD group. e Qtracker® 800-labelled WJ-MSCs were traced in vivo using the IVIS Spectrum in vivo imaging system. Fluorescent signals were strongest at the injection site after 1 h and persisted for up to 72 h

Back to article page